The Role of Public-Sector Research in the Discovery of Drugs and Vaccines. [Ip-health] Novartis and Gleevec. A Conversation With Brian J. Druker, M.D. - Researcher Behind the Drug Gleevec - Interview. Glivec debate poses vital issues. Glivec debate poses vital issues Limb Jae-un May 18, 2002 A patient dying of leukemia in a Seoul hospital was placed in a clinical trial in April 2001 as a last attempt to save his life. After taking an experimental drug for nine days, the patient was discharged healthy and is now leading a normal life and working everyday. The drug credited with saving the man's life, Glivec (imatinib mysylate), has been the object of a year-long brawl over its price, involving Novartis AG, the Swiss pharmaceutical giant, the Korean government and health care activists.
Not surprisingly, the fight has become emotional, underscoring exactly what is at stake life or death. Despite the government's promise to announce a compromise decision on the pricing on Monday, the controversy seems far from over, and patients who cannot afford the treatment find their lives waning in a crossfire of charges of greed, insensitivity and ignorance. But some are not swayed by that argument. Research Guide on TRIPS and Compulsory Licensing. Research Guide on TRIPS and Compulsory Licensing: Access to Innovative Pharmaceuticals for Least Developed Countries by Do Hyung Kim Do Hyung Kim is a J.D. candidate at the University of Houston Law Center, where he is concurrently pursuing a Masters in Public Health at the University of Texas School of Public Health.
Mr. Kim earned his B.S. in Electrical Engineering from the University of Texas at Austin. Published February 2007 Table of Contents A. B. A. B. C. D. A. B. C. Innovative pharmaceutical companies have rapidly invented new medicines to fight against chronic conditions and notorious diseases such as AIDS that have plagued the worldwide population. This research guide will focus on legal and economic factors surrounding the global problem of gaining access to innovative drugs. So how did TRIPS marry intellectual property law with international trade regulations? Still, the Doha Declaration fell short of its objective to "promote access to medicines for all. Gleevec. Glivecpromopostersi.pdf (application/pdf Object)
Chronic Myelogenous Leukemia - Imatinib Therapy and Interferon Therapy for CML – HealthTree. Chronic myelogenous leukemia (CML) is a cancer of the bone marrow. In its initial stages, CML develops slowly, but the disease accelerates rapidly in its final phase. CML occurs because of a chromosomal translocation where part of chromosome 9 switches places with chromosome 22.
This translocation results in the Philadelphia chromosome, triggering excessive production of abnormal white blood cells. Chronic myelogenous leukemia treatment may include imatinib therapy, interferon therapy, a bone marrow transplant or cord blood transplantation. Stages of Chronic Myelogenous Leukemia Chronic myelogenous leukemia has three phases, and treatment depends on the disease’s stage at the time of diagnosis: Chronic CML: White blood cell levels build up slowly for two to five years, often without noticeable symptoms.Accelerated CML: Immature white blood cells called blasts accumulate in the blood, bone marrow, spleen and liver. Imatinib Therapy Stem Cell Transplants Resources Mayo Clinic. (2008). Novartis's Ranjit Shahani: Patenting Innovation 'Is the Best Protection for Patients' - India Knowledge@Wharton. Concern is growing that patents hinder access to life-saving drugs in developing countries.
While India clearly has made progress in advancing intellectual property rights, more needs to be done to align the country’s approach with international obligations and standards. In an interview with India Knowledge@Wharton, Ranjit Shahani, country president of the Novartis Group in India, spoke about the importance of safeguarding intellectual property and its impact on affordability and access to medicine. Novartis is challenging the denial of a patent for its cancer drug Glivec, as it is known in India. (In the U.S., the drug is called Gleevec.)
Shahani was president of the Organization of Pharmaceutical Producers of India (OPPI) from 2001 to 2007, is president of the Bombay Chamber of Commerce and Industry and chairman of INTERPAT in India, and was on the council of the International Federation of Pharmaceutical Manufacturers & Associations. Shahani: No. Does Novartis Hate Whistleblowers? You be the judge after reading this story. I didn't realize that I should probably write this article, until I got involved in the more recent Novartis Whistleblower story with David Olagunju, who was fired after he objected to Novartis messing around with clinical data - at least that is what he claims in his lawsuit. So here's what happened to me, which made me wonder, a few years back: Does Novartis hate whistleblowers? I had decided to look for work in another drug company. So I wrote an e-mail to Dr. Daniel Vasella, CEO of Novartis. He was apparently impressed, because he responded right away and set up a meeting for me with Thomas Ebeling, his right-hand man, who had joined Novartis from PepsiCo, and was CEO of Novartis' pharmaceutical business.
We met at Short Hills Hilton in NJ, and the interview went well. So I was whisked over to Basel, Switzerland, and met with Dr. I also met Novartis' Head of Global HR. And that's when something happened. Click on images below to read . . . Activities - Public Eye Swiss Award 2007 - Glivec Novartis. Affordable Drugs: Campaign for Affordable Trastuzumab Open letter to the Prime Minister of India Shri Manmohan Singh About Glivec The "Public Eye Swiss Award 2007" for Irresponsible Corporate Behaviour goes to Novartis On the opening day of the World Economic Forum in Davos, Switzerland, the Public Eye Swiss Award 2007 for irresponsible corporate behaviour was given to Novartis International on the basis of a nomination made by Cancer Patients Aid Association (CPAA).
The Berne Declaration and Pro Natura, Switzerland, have given out this negative award for the last three years. Novartis, a Basel based pharmaceutical company is currently using patent lawsuits in an attempt to limit access to affordable generic drugs in India and developing countries. Speech by Mr. Dear friends, The Glivec Story India has around 30,000 cases of Chronic Myeloid Leukemia (CML) reported every year. CPAA went to the Supreme Court of India against granting of EMR to Novartis. Articles: [Top] 18 August 2009, New Delhi. Generic Gleevec?: The Leukemia & Lymphoma Society Community.
Novartis' Gleevec Patent Challenged in the US? Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients. (Pr)Tasigna surpassed gold standard in all designated measures of efficacy, including prevention of disease progression at 12 months CML is one of the four most common types of leukemia. It is caused by an abnormal chromosome, called the Philadelphia (Ph) chromosome which produces an abnormal cancer protein called Bcr-Abl, which is responsible for blocking the normal signal that tells the body to stop producing white blood cells. As a result, CML patients have a significantly elevated cancerous white blood cell count.
A form of blood cancer, CML is estimated to affect approximately 3,000 Canadians. Without treatment, CML typically progresses over three to five years from the initial (chronic) phase through a transition period (accelerated phase) to a rapidly fatal form (blast crisis). Can Novartis drug fill Gleevec's shoes? It's a good-news, bad-news sort of day for Novartis' cancer drugs.
First, the good news: Tasigna won European Union approval for treatment of chronic myeloid leukemia. A potential follow-up to Gleevec, Novartis' second best-selling drug with $2.55 billion in revenues last year, Tasigna was approved in the U.S. last month. The bad news? FDA accepted a Paragraph IV generic challenge to Gleevec from India's Sun Pharmaceutical.
Enter Tasigna.